American Academy of Neurology Annual Meeting

May 19, 2022

The chief medical partner of neurology, ophthalmology, and internal medicine at Genentech shared his perspective on the steps the field has taken to improve clinical trials and therapies for neurodegenerative diseases such as Alzheimer disease. [WATCH TIME: 3 minutes]

May 19, 2022

The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against recommending approval for AMX0035 in ALS. [WATCH TIME: 3 minutes]

May 18, 2022

The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps to justify whether reflex tears are a reliable biomarker for Parkinson disease.

May 11, 2022

The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the efforts needed to validate tears as a biomarker in patients who don’t present with typical Parkinson disease. [WATCH TIME: 4 minutes]

May 09, 2022

The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps in how we can expand on tears as a valuable biomarker for neurodegenerative diseases. [WATCH TIME: 4 minutes]

May 06, 2022

The director of the Division of Movement Disorders at the USC Keck School of Medicine commented on the potential of reflex tears as a critical biomarker of Parkinson disease. [WATCH TIME: 6 minutes]

May 03, 2022

Using this new methodology, 78% of patients with progressive multiple sclerosis demonstrated large treatment benefits with the siponimod (Mayzent; Novartis) on at least 1 of 4 clinical outcomes.

May 02, 2022

The professor of neurology at the University of Basel provided insight on a new methodology that allows depiction of patient profiles from baseline characteristics and their associations with individual outcomes. [WATCH NOW: 5 minutes]

April 29, 2022

Peter J. McAllister, MD, FAAN, medical director and chief medical officer, New England Center for Neurology and Headache, offered his insight into data from the phase 2 STEMTRA trial in TBI and the trends he’s observed in the field of regenerative medicine.

April 28, 2022

Expert clinicians offer their insight on the associations between stroke and COVID-19, treatment for traumatic brain injury, the latest on aducanumab, priorities for research in migraine, and more, from the 2022 American Academy of Neurology Annual Meeting.